Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
09
2021
accepted:
05
08
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Metabolomics provides a powerful tool to study physiological changes in response to various perturbations such as vaccination. We explored whether metabolomic changes could be seen after vaccination in a phase I trial where Gabonese adults living either in rural or semi-urban areas received the subunit hookworm vaccine candidates (Na-GST-1 and Na-APR-1 (M74) adjuvanted with Alhydrogel plus GLA-AF (n = 24) or the hepatitis B vaccine (n = 8) as control. Urine samples were collected and assayed using targeted 1H NMR spectroscopy. At baseline, a set of metabolites significantly distinguished rural from semi-urban individuals. The pre- and post-vaccination comparisons indicated significant changes in few metabolites but only one day after the first vaccination. There was no relationship with immunogenicity. In conclusion, in a small phase 1 trial, urinary metabolomics could distinguish volunteers with different environmental exposures and reflected the safety of the vaccines but did not show a relationship to immunogenicity.
Identifiants
pubmed: 36155987
doi: 10.1371/journal.pone.0275013
pii: PONE-D-21-30030
pmc: PMC9512193
doi:
Substances chimiques
Adjuvants, Immunologic
0
Hepatitis B Vaccines
0
Aluminum Hydroxide
5QB0T2IUN0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275013Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nature. 2008 May 15;453(7193):396-400
pubmed: 18425110
Electrophoresis. 2010 Jul;31(14):2349-55
pubmed: 20575107
Hypertens Res. 2012 Apr;35(4):404-12
pubmed: 22089538
Cell. 2017 May 18;169(5):862-877.e17
pubmed: 28502771
Front Microbiol. 2017 Oct 13;8:1979
pubmed: 29081768
Lancet Infect Dis. 2021 Feb;21(2):275-285
pubmed: 32926834
Nat Protoc. 2007;2(11):2692-703
pubmed: 18007604
Sci Rep. 2018 May 25;8(1):8149
pubmed: 29802315
J Infect Dis. 1993 Oct;168(4):881-7
pubmed: 8376833
Arch Toxicol. 1991;65(7):548-55
pubmed: 1685880
Vaccine. 2017 Mar 1;35(9):1238-1245
pubmed: 28169076
BMC Med. 2018 Nov 8;16(1):202
pubmed: 30404627
Xenobiotica. 1999 Nov;29(11):1181-9
pubmed: 10598751
Vaccine. 2013 Apr 18;31 Suppl 2:B227-32
pubmed: 23598487
Springerplus. 2014 Jul 29;3:388
pubmed: 25120947
J Infect Dis. 2010 May 15;201(10):1561-9
pubmed: 20367477
Protein Expr Purif. 2012 Jun;83(2):145-51
pubmed: 22503665
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Front Immunol. 2016 Feb 29;7:44
pubmed: 26973643
PLoS Negl Trop Dis. 2018 Aug 6;12(8):e0006663
pubmed: 30080853
PLoS One. 2020 May 22;15(5):e0233213
pubmed: 32442208
Hum Vaccin. 2010 Jul;6(7):532-42
pubmed: 20622508
J Infect Dis. 2007 Dec 1;196(11):1671-8
pubmed: 18008252
Toxicol Pathol. 2008 Jan;36(1):140-7
pubmed: 18337232
Metabolites. 2020 Nov 30;10(12):
pubmed: 33266347
Vaccine. 2016 Apr 27;34(19):2197-206
pubmed: 27002501
Front Immunol. 2017 Sep 13;8:1134
pubmed: 28955344
Toxicol Appl Pharmacol. 2003 Mar 15;187(3):137-46
pubmed: 12662897
J Proteome Res. 2020 Aug 7;19(8):3264-3275
pubmed: 32434331
Clin Pharmacol Ther. 2010 Sep;88(3):394-9
pubmed: 20668441